REMOVAL OF ZINC IS REQUIRED FOR PROCESSING OF THE MATURE NUCLEOCAPSID PROTEIN OF HUMAN-IMMUNODEFICIENCY-VIRUS, TYPE-1, BY THE VIRAL PROTEASE

被引:0
|
作者
WONDRAK, EM
SAKAGUCHI, K
RICE, WG
KUN, E
KIMMEL, AR
LOUIS, JM
机构
[1] NIDDK,CELLULAR & DEV BIOL LAB,BETHESDA,MD 20892
[2] NCI,CELL BIOL LAB,BETHESDA,MD 20892
[3] NCI,FREDERICK CANC RES & DEV CTR,PROGRAM RESOURCES INC DYNCORP,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702
[4] SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,ENVIRONM TOXICOL & CHEM LAB,TIBURON,CA 94920
[5] SAN FRANCISCO STATE UNIV,ROMBERG TIBURON CTR,OCTAMER INC,TIBURON,CA 94920
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In human immunodeficiency virus, RNA selection and packaging during assembly involve the two retroviral-type fingers of the nucleocapsid protein that are held in a constrained configuration by coordinated zinc ions, In this report, we demonstrate that the nucleocapsid protein in a metal bound state is resistant to cleavage by the viral protease, but upon removal of zinc ions by chelating agents, it is hydrolyzed within the first zinc finger between Phe-16 and Asn-17. However, 3-nitrosobenzamide and cupric ions, which release zinc through oxidation of the cysteine residues of the finger, render the nucleocapsid protein resistant to cleavage. Since protease inhibitors and 3-nitrosobenzamide restrict processes relating to steps early in infection, the cleavage of the nucleocapsid protein may represent an essential event that can be exploited for the design of novel antiviral agents.
引用
收藏
页码:21948 / 21950
页数:3
相关论文
共 50 条
  • [41] DNA FOUND IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 PARTICLES MAY NOT BE REQUIRED FOR INFECTIVITY
    ARTS, EJ
    MAK, J
    KLEIMAN, L
    WAINBERG, MA
    JOURNAL OF GENERAL VIROLOGY, 1994, 75 : 1605 - 1613
  • [42] VPR IS REQUIRED FOR EFFICIENT REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN MONONUCLEAR PHAGOCYTES
    CONNOR, RI
    CHEN, BK
    CHOE, S
    LANDAU, NR
    VIROLOGY, 1995, 206 (02) : 935 - 944
  • [43] TRANSMISSION AND PATHOGENESIS OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    CONNOR, RI
    HO, DD
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1994, 10 (04) : 321 - 323
  • [44] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION OF THE BRAIN
    ATWOOD, WJ
    BERGER, JR
    KADERMAN, R
    TORNATORE, CS
    MAJOR, EO
    CLINICAL MICROBIOLOGY REVIEWS, 1993, 6 (04) : 339 - 366
  • [45] ENHANCED PROTEOLYTIC PROCESSING OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ENVELOPE PROTEIN IN MURINE LTK(-) CELLS
    RODRIGUEZ, D
    RODRIGUEZ, JR
    ESTEBAN, M
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 1995, 11 (01) : 81 - 85
  • [46] CELLULAR LATENCY OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1
    POMERANTZ, RJ
    BAGASRA, O
    BALTIMORE, D
    CURRENT OPINION IN IMMUNOLOGY, 1992, 4 (04) : 475 - 480
  • [47] INACTIVATION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 BY ALCOHOLS
    VANBUEREN, J
    LARKIN, DP
    SIMPSON, RA
    JOURNAL OF HOSPITAL INFECTION, 1994, 28 (02) : 137 - 148
  • [48] HEADACHE AND THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    HOLLOWAY, RG
    KIEBURTZ, KD
    HEADACHE, 1995, 35 (05): : 245 - 255
  • [50] HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 AND CYTOMEGALOVIRUS IN SALIVA
    LUCHT, E
    ALBERT, J
    LINDE, A
    XU, WM
    BRYTTING, M
    LUNDEBERG, J
    UHLEN, M
    BRATT, G
    SANDSTROM, E
    HEIMDAHL, A
    NORD, CE
    WAHREN, B
    JOURNAL OF MEDICAL VIROLOGY, 1993, 39 (02) : 156 - 162